Trial Site Detail
Drug: |
AUY922 |
|||
|---|---|---|---|---|
Trial: |
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients. |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Ongoing, but not recruiting |
|||
Dana Farber Cancer Institute450 Brookline Ave |
Principal Investigator: |
Stephen Hodi, MD, PhD |
|---|---|
Contact: |
617 632-5053 stephen_hodi@dfci.harvard.edu |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Dana Farber Cancer Institute Website: |
http://www.dana-farber.org/Research/Clinical-Trials.aspx |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.